Search

Displaying results 681 - 690 of 4691 in total
  1. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

  2. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  3. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910]

  4. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market. … It was initially marketed by Pharmuka.

  5. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]

  6. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]

  7. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    [A27210] Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen. … It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class

  8. Drug

    Hydroxocobalamin

    go.drugbank.com/drugs/DB00200
    ApprovedInvestigational

    Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.

  9. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.

  10. Drug

    Desogestrel

    go.drugbank.com/drugs/DB00304
    ApprovedInvestigational

    [A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … [F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].